HomeStartups QTREX Quantum lifecycle

Claimed by owner Last Update Jun 9, 2026 Suggest Edits Claim Profile

Claimed by owner

QTREX Quantum

Former names: Insense Medical, Inspira Technologies, CLEARX MEDICAL

AME Connectivity Hardware for Quantum and Mission-critical Systems

PUBLIC on NASDAQ on Jul 2021

QTREX Quantum

QTREX Quantum Overview

Cumulative Funding Raised Over Time ($)

Employees Over Time

QTREX Announces Pricing of a $10 Million Private Placement of Ordinary Shares with a New Fundamental Institutional Investor

QTREX in Advanced Discussions with Top-Five Global Quantum Computing Company Regarding Strategic Collaboration

Inspira Technologies to Begin Trading as QTREX Quantum Under Nasdaq Ticker "QTEX"

Inspira Technologies Rebrands as QTREX Quantum and Changes Nasdaq Ticker to QTEX

Inspira Technologies to Begin Trading as QTREX Quantum Under Nasdaq Ticker "QTEX" on May 20, 2026, Following Strategic Focus on AME and Quantum Connectivity

NYU Langone Issues $580,000 Purchase Order for Inspira's FDA-Cleared ART100 Following Multi-Patient Hospital Evaluation

Inspira Technologies CEO Issues Letter to Shareholders on Strategic Direction and Value Creation Plan

Inspira Secures $596,000 AME System Order from Leading Irish Technological University

Inspira and Qarakal Sign Joint Development Agreement for Cryogenic Interconnects in Superconducting Quantum Systems

Inspira Technologies Secures Fully Paid $390,000 Purchase Order and Recurring Revenue Stream from Premier APAC University

Inspira Completes Commercial Deployment of its AME System at a Tier-1 U.S. Defense Entity

Inspira Technologies Appoints Yoav Rozanovich as Chief Business Officer to Drive Immediate Revenue Growth and Quantum Expansion

Inspira Begins AME Technology Implementation Process with One of the World's 10 Largest U.S. Based Companies

Nano Dimension Announces the Sale of AME and Fabrica Product Lines

Inspira Technologies Announces Acquisition of the AME Platform from Nano Dimension

Inspira Enters Quantum Computing Sector, Targeting a Critical Connectivity Bottleneck with Newly Acquired AME Platform

Inspira Technologies Terminates ATM and SEPA Equity Facilities to Prepare for Next Strategic Phase

Inspira Technologies Reports Full Year 2025 Financial Results and Provides Business Updates

Inspira Receives Nasdaq Notification Regarding Minimum Market Value Deficiency

Inspira Expands U.S. Commercial Footprint: Deploys ART100 at a New Premier New York Academic Medical Center, Ranked Top 10 in New York State

#Product Stage #Customers #FDA approved/pending approval

Inspira Accelerates U.S. Commercial Strategy: FDA-Cleared ART100 Targets Market Adoption at AmSECT 2026 via Glo-Med Networks

#Product Stage #Partners #FDA approved/pending approval

Inspira Technologies Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Requirement

Inspira Secures Vendor Approval from $12 Billion Revenue HMO (World’s 2nd Largest), Enabling Immediate ART100 Deployment

#Customers

Inspira Announces Pricing of $4.75 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

#PIPE/PO

Inspira Technologies Validates Next-Gen Standalone HYLA™ Blood Sensor with Clinical-Grade Accuracy, Targeting $48 Billion Heart-Lung Surgery Market

#Product Stage #FDA approved/pending approval

ART100 Becomes Inspira’s First System to Complete Clinical Evaluation and Enters Budgeted Procurement at Top U.S. Medical Center

#Product Stage #Customers

Inspira Advances to Final Governmental Budgetary Validation Procedures for Previously Announced Binding Purchase Orders

Inspira Outlines Strategic Vision and Transaction Framework for Breast Cancer Liquid Biopsy Expansion

#Acquisition #Investment

Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Concurrent $15 Million Investment at $180 Million Valuation

#Acquisition #Investment

CORRECTION – Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Investment of $15 Million into Inspira at $180 Million Valuation

#Acquisition #Investment

Inspira Technologies Reaffirms $49.5 Million in Binding Purchase Orders and Aligns Execution with 2026 Regulatory and Deployment Milestones

#Customers #Partners

Inspira Announces $1.8 Million Registered Direct Offering Priced At-The-Market and Additional Equity Financing Agreement to Support Ongoing Commercial Execution

#PIPE/PO

Inspira Technologies Granted Patent in Japan for the INSPIRA™ ART System's Convertible Dual Lumen Cannula Device and Method of Use

#Product Stage

Inspira Technologies Announces Strategic Leap in Lab Capabilities – Accelerating Next-Generation Diagnostics and Blood Technology

#Expand

Inspira Completes Clinical Study for HYLA™ Blood Sensor - Ahead of Regulatory Submission

#Product Stage #FDA approved/pending approval

Inspira Technologies Nears Final Regulatory Clearance for the ART100 in the UAE, Accelerating Gulf Region Expansion

#Product Stage #Customers #Partners

Inspira and Bites Form Strategic Alliance to Embed AI as a Core Standard Across Inspira’s Global Ecosystem

#Partners #Customers

Inspira Appoints Former Johnson & Johnson Executive as VP of Global Sales and New Board Member from a Leading International Investment Firm

#Management Changes

Inspira Appoints Former Johnson & Johnson Senior Business Manager as VP of Global Sales and New Board Member from a Leading International Investment Firm

#Management Changes

Inspira Technologies Reports First Half 2025 Financial Results and Issues Business Update

#Product Stage #Customers #FDA approved/pending approval #Partners

All You Need to Know About Inspira Technologies OXY (IINN) Rating Upgrade to Buy

Inspira to Unveil HYLA™ Real-Time Blood Sensor at U.S. ELSO; 97.35% Accuracy Confirmed

#Product Stage #Partners

Inspira Announces 97.3% Accuracy Results for HYLA™ Blood Sensor, Advancing Toward FDA Submission for Clearance

#Product Stage #FDA approved/pending approval

When Will Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) Become Profitable?

Top U.S. Honor Roll Hospital Expands Use of INSPIRA™ ART100 System to Lung Transplant Procedures

#Customers #Product Stage

Inspira Receives U.S. Patent Approval for the ART500 Core Technology, Key Patent Positions the Company to Dominate $20 Billion Estimated Market

#Product Stage #FDA approved/pending approval

Inspira Secures $27 Million Government Binding Purchase Order for ART100 Systems with Full Payment in 2025

#Customers #Partners

Inspira Clarifies Routine Nature of Registration Statement on Form F-3 Filing Performed Every Three Years

#Product Stage #FDA approved/pending approval

Inspira Activates U.S. Based Consulting Firm to Execute Transformational Initiatives

#Partners #Customers #Product Stage

Inspira Regains Compliance with Nasdaq Minimum Bid Price Requirement

#Product Stage #Customers #Partners #Investment

Inspira Achieves All Key Objectives in Previously Announced Government Talks, Forging a Pathway to National Adoption and Global Scale-Up of the ART100

#Partners #Customers

Inspira in High-Level Government Talks to Advance National Integration of the ART100 and Establish a Global Distribution Framework

#Customers #Partners

Inspira Technologies Secures $22.5 Million Purchase Order, Launches Full Revenue Execution Phase

#Customers #Product Stage

Inspira Technologies says ART100 in use at Tier-1 U.S. hospitals

#Product Stage #Customers

Inspira’s ART100 in Use at Tier-1 U.S. Hospitals, Generating Strong Clinical Interest and Accelerating Sales Discussions

#Product Stage #Customers #FDA approved/pending approval

Inspira Technologies scales up ART100 production capabilities

#Product Stage #Customers #Management Changes

Inspira Scales Up ART100 Production Capabilities Amid Advanced Negotiation with European Government Authority

#Product Stage #Customers #FDA approved/pending approval

CORRECTION - Inspira Scales Up ART100 Production Capabilities Amid Advanced Negotiation with European Government Authority

#Product Stage #Customers #FDA approved/pending approval

Inspira Technologies Initiates Global Commercial Rollout of FDA-Cleared ART100 System

#Product Stage #Customers #FDA approved/pending approval

Inspira Technologies Aligns Executive Team Amid Corporate Structuring Initiatives

#Management Changes

INSPIRA ART100 System Approved by Israel's Largest Healthcare Provider for Use in Organ Transplant Patients

#Product Stage #Customers

Inspira Achieves above 99% Gas Exchange Efficiency in VORTX™ Technology In-Vivo Animal Testing

#Product Stage #FDA approved/pending approval

Inspira Technologies Generates First Revenues from Deployment of INSPIRA ART100 Systems

#Product Stage #Customers #Partners

Inspira Technologies Announces Successful Treatment of First Patient with INSPIRA ART100 at Westchester Medical Center

#Product Stage #Customers #Partners

Inspira Technologies Announces Successful Installation of INSPIRA ART100 Systems in Premier U.S. Hospital

#Product Stage #Customers

Market Alert: Inspira Technologies' Respiratory Tech Could Transform $19B Ventilator Market Amid Major Wave of Multi Billion Dollar Medtech Acquisitions

#Product Stage #Customers

Inspira Technologies' Innovative Life-Support System to be Showcased at AmSECT 63rd International Conference 2025 in San Diego

#Product Stage #Partners

PESG Report: Inspira Technologies' AI-Powered Respiratory System Could Revolutionize Care for 20 Million Annual ICU Patients in Combined $25+ Billion Market

#Product Stage #FDA approved/pending approval

/PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. ("Inspira," "Inspira Technologies" or the "Company") (Nasdaq: IINN), a pioneering force in the evolution...

Inspira Technologies Releases CEO Update: Major Milestones Signal Next-Level Respiratory Care

#Product Stage #FDA approved/pending approval

Inspira Technologies Receives Nasdaq Notification Regarding Minimum Bid Requirement

/PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic...

/PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic...

Inspira Technologies Reports Full Year 2024 Financial Results and Provides Business Updates

#Product Stage #Partners #Management Changes #FDA approved/pending approval

PESG Report: Inspira Technologies Breaks new Ground with Positive Clinical Data for AI-Powered Blood Sensor Exceeding Expectations

#Product Stage #Customers #Partners #FDA approved/pending approval

Inspira Technologies Announces Positive Results from Clinical Study of HYLA Blood Sensor, Achieving 96% Accuracy

#Product Stage

EXCLUSIVE: Inspira and Ennocure's Bio-Electronic Tech Uses Electric Stimulation to Help Prevent IV-Related Infections

#Product Stage #Partners

Inspira Achieves Positive Results of Above 95% For Preventing Bloodstream Infections

#Product Stage #Partners #FDA approved/pending approval

/PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in breakthrough life-support technology, today...

#Product Stage #Partners

Inspira Technologies Oxy B.H.N. Ltd. (IINN) Enhances HYLA™ Sensor with AI Oxygenation Indicator

PESG Report: Inspira Technologies Strengthens its AI-Powered Blood Sensor with new Capabilities, Intends to Share Clinical Findings Soon

#Product Stage #FDA approved/pending approval

/PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in breakthrough life-support technology, today...

#Product Stage #FDA approved/pending approval

EXCLUSIVE: Isreal-Based Inspira Technologies Integrates New Oxygenation Indicator Into HYLA Blood Sensor To Enhance Critical Care Monitoring

#Product Stage

Inspira Technologies Integrates New Oxygenation Indicator into AI-Powered HYLA Blood Sensor

#Product Stage #FDA approved/pending approval

Inspira™ Introduces Advanced Features for INSPIRA™ ART100, Further Amplifying User and System Support

#Product Stage

Inspira™ Technologies Prepares its First Life-Support Systems for Deployment at a Leading U.S. Hospital

#Product Stage #Customers #Partners

/PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW), ("Inspira Technologies," "Inspira" or the "Company"), a groundbreaking...

#Product Stage #FDA approved/pending approval

Inspira™ Announces the Appointment of Tal Parnes as the New Chairman of the Board, Bringing Vast Experience in the Medical Technology and Pharmaceutical Sectors

#Management Changes

/PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology...

#Management Changes

Inspira™ Technologies Collaborates With Zriha Medical To Launch Cutting-Edge Production Line

#Partners

Inspira™ Technologies Unveils Modular Configuration for Revolutionary VORTX™ Blood Oxygenation Delivery Technology

/PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, is...

#Product Stage #FDA approved/pending approval

EXCLUSIVE: Inspira Technologies Unveils Modular Configuration For VORTX Blood Oxygenation Delivery Technology

#Expand

Inspira™ Preparing Production in Response to Spread of Respiratory Virus in China

#Product Stage

/PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW), ("Inspira Technologies," "Inspira" or the "Company"), a groundbreaking...

#Product Stage #FDA approved/pending approval #Partners

Inspira™ Technologies Flagship Technology to be Showcased at Arab Health Expo 2025 in Dubai

#FDA approved #Partners

Inspira™ Announces Pricing of $3.2M Private Placement by New and Existing Investors of the Company

#Investment

Inspira™ Technologies Delivers Systems to Leading Distributor for U.S. Deployment

#Customers #Partners

/PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN, IINNW), ("Inspira Technologies," "Inspira" or the "Company"), a groundbreaking respiratory...

#Customers #Partners

Inspira™ Expands HYLA™ Blood Sensor Technology into Personalized Blood Lab Testing for Rapid Detection of Serious Medical Conditions

#Expand

/PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN, IINNW), ("Inspira Technologies" or the "Company"), a groundbreaking life support technology...

Inspira™ Collaborates with New York's Westchester Medical Center to Evaluate the INSPIRA™ ART100 Functionality and Performance in Clinical Scenarios

#Partners

/PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN), (Nasdaq: IINNW) ("Inspira Technologies", "Inspira" or the "Company"), a groundbreaking...

#Partners

Join Inspira™ Technologies' Live Investor Webinar and Q&A Session on November 11

/PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN), ("Inspira Technologies" or the "Company"), an innovative medical technology company in the...

/PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira Technologies", "Inspira" or the "Company"), a groundbreaking life support...

#Partners

Inspira™ Announces Establishment of Distribution Facility to Support U.S. Deployment of INSPIRA™ ART100

#Partners #Customers

Inspira™ Announces Development of New Disposable Kit with Built-In Performance Monitoring Mechanism

#Customers

Inspira Stock to Gain From its Appearance at Annual ELSO Conference

#Customers #Partners

Inspira™ Launches INSPIRA™ ART100 at the World's Largest Extracorporeal Life Support Conference

#Customers #Partners

IINN Stock Gains on Second US Patent Approval for VORTX System

#Investment

Inspira gains new US patent approval for blood oxygenation system

#Investment

Inspira™ Secures a Second U.S. Patent Approval for Orbiting Blood Oxygenation Delivery System

Favorable Clinical Results for HYLA Sensor Might Boost Inspira Stock

#Expand

/PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology...

#Expand

Inspira™ to Publish HYLA™ Clinical Results in Fourth Quarter 2024

#Customers #Expand

INSPIRA (IINN) CART Gets FDA Listing, to Enhance Healthcare

#Customers #Partners #Expand

Inspira™ Technologies Announces FDA Listing and Market Readiness of New Product

#Customers #Partners #Expand

Inspira™ Approached by Large Medical Company to Evaluate Operation of their Key Product with INSPIRA™ ART100 - Results Exceed 100% at Maximum Flow

Inspira™ Technologies Introduces the INSPIRA Cardi-ART, Aiming to Provide Oxygen to the Brain During Cardiac Arrest

#Investment, Expand

Inspira Technologies gains key Israeli approval for INSPIRA ART100 system

#Customers #Partners

Inspira™ Receives Israeli Regulatory Approval for the INSPIRA™ ART100 System

#Customers #Expand

Inspira (IINN) Unveils Business Targets for 2024-25

#Customers #Partners #Expand

Inspira™ Announces Business Plan Targets

#Customers #Partners #Expand

Inspira™ Introduces Advanced Life Support Solutions to Key International Leaders at the Annual iECOs Conference in Israel

#Customers, Expand

Inspira™ Receives First Ever Purchase Order for INSPIRA™ ART100 Systems in the U.S.

#Customers #Partners #Expand

Inspira™ to Exhibit the FDA Cleared INSPIRA™ ART100 System at a World-Renowned Event in the Sector

#Customers, Partners

Inspira™ Technologies Announces Business Targets Presentation Following FDA Clearance and Significant Developments

#Management Changes #Partners

Inspira Technologies' (IINN) ART100 Gets FDA 510(k) Grant

#Investment #Partners

INSPIRA™ ART100 Receives FDA 510(k) Clearance

#Investment #Partners

Inspira™ Announces Start of Production of the INSPIRA™ ART100

#Customers #Partners

Inspira™ Receives CSA Certification of Compliance to U.S. Standards for the INSPIRA™ ART100

#Customers

Inspira™ Signs Term Sheet for Use of INSPIRA™ ART100 Device in Organ Transplant Procedures

#Partners

Inspira™ and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth that Causes Bloodstream Infections

#Partners, Research and Development

Inspira™ Announces Program to Pioneer the Applicable Use of the INSPIRA™ ART100 Device for an Artificial Womb

#Customers #Expand

Inspira™ Announces $1.65 Million Registered Direct Offering of Ordinary Shares by Inspira CEO's Mother with Leading Fund Manager

#Investment

Companies Like Inspira Technologies Oxy B.H.N (NASDAQ:IINN) Could Be Quite Risky

#Investment

Inspira™ Technologies Reports Full Year 2023 Financial Results

#Customers #Partners #Management Changes

Inspira Technologies (IINN) Strives to Get AMAR Nod for ART100

#Customers #Expand

Inspira™ Announces AMAR Regulatory Submission of the INSPIRA™ ART100, to Enter the Southeast Asia and South American Markets

#Customers #Expand

Inspira Technologies (IINN) Releases Favorable Data on VORTX

#Customers #Investment

Inspira™ Releases New Data Demonstrating Superiority of its Core Technology, Across Key Endpoints of HMSS Indicator

#Investment

Inspira™ Announces Plans to Report the Primary Results for a Core Blood Oxygenation Technology Within Days

#Investment #Expand

Inspira™ To Host Conference Call to Discuss Investor Presentation and Announce Next Major Milestone

Inspira™ Announces Breakthrough Update: Nears First FDA 510(k) Approval, 3 U.S. Patents Approved, $546 million in Summary Distribution Agreements

#Customers #Partners #Investment

Inspira™ introduces high-end platform for bio-mimicking blood parameters for development and testing of core technologies

#Investment, Expand

15 Hot Penny Stocks On the Move

#Investment

Inspira™ Receives First Ever U.S. Patent Approval for an Orbiting Blood Oxygenation Delivery System

#Customers #Investment

Inspira™ Technologies Collaborates with a Leading Israeli Medical Center for Clinical Evaluation of INSPIRA™ ART Device

#Partners

Inspira™ Technologies Signs Strategic Agreement to Enter Gulf States with Glo-Med for Deployment of 531 INSPIRA™ ART Devices

#Partners #Expand

Inspira™ Announces Plans to Launch and Target Single-Use Disposable Blood Oxygenation Kit for a New Disposable Perfusion Market Opportunity

#Customers #Expand

Inspira™ Technologies Signs Letter of Intent with Northwestern Memorial Hospital in Chicago for Clinical Use of INSPIRA™ ART100 Device

#Partners #Expand

Inspira™ Technologies Closes on $3.88 Million Registered Direct Offering

#Investment

Inspira Announces $3.88 Million Registered Direct Offering

#Investment

Inspira™ Announces 95% Accuracy Results for HYLA™ Blood Sensor, Planning FDA Submission for Clearance in 2024

#Customers #Partners

Inspira Technologies to Participate in J.P. Morgan Healthcare Conference

#Management Changes #Expand

In Preparation for FDA Clearance and Device Deployment, Inspira has Appointed Dr. Dan Gorfil, to Medical Advisory Board

#Management Changes

Inspira (IINN) Expands in Life Support Space With New Deal

#Partners

Inspira Collaborates with Ennocure for development of a Proprietary Bio-Electronic Treatment to Prevent Associated Bloodstream Infections in ICU Patients

#Partners #Expand

Inspira™ Technologies Reports Third Quarter 2023 Financial Results

#Investment #Expand

Inspira™ Announces Israeli Innovation Authority Grant for New VORTX™ Disposable Blood Oxygenation Technology

#Investment

Inspira™ Granted U.S. Patent for INSPIRA™ ART500 Medical Device

#Investment

Inspira™ Terminates ATM Program and Provides an Update

#Customers #Partners

Inspira™ Enters into a Distribution Agreement in Central America with CIO MED GROUP

#Partners #Expand

Inspira™ Technologies Unveils the INSPIRA™ ART Line of Medical Devices at the World's Largest Extracorporeal Life Support Conference

#Customers #Partners

Inspira™ Announces 510(k) FDA Submission of INSPIRA™ ART100 Towards Commercialization

#Investment #Expand

Inspira (IINN) Advances Foothold in Europe With Extended Deal

#Partners #Customers

Inspira™ Signs Agreement Expansion with Innovimed for Clinical Trials of INSPIRA™ ART Respiratory Medical Devices

#Partners

Inspira™ Technologies Reports Second Quarter 2023 Financial Results

INSPIRA™ ART100 Completes Usability Study in Boston Massachusetts, U.S.

#Customers #Expand

Inspira™ Technologies Receives Certification of Medical Devices Quality Management Systems, Another Step Towards EU Regulatory Approval

#Customers

Inspira™ Technologies Enters into Collaboration Agreement with U.S.-Based Perfusion Solution Inc.

#Partners

Inspira™ Technologies Unveils Investor Deck Showcasing Revolutionary Advancement in Acute Respiratory Care

#Investment #Partners

Inspira Technologies Appoints Dr. Nir as Chief Medical Officer

#Management Changes

Inspira™ Technologies Reports First Quarter 2023 Financial Results

#Investment #Expand

Inspira™ Technologies will Reveal the New ALICE™ Device at the World's Largest Extracorporeal Life Support Conference

#Partners #Investment

Inspira™ Technologies is Developing the VORTX™ Blood Oxygenator, a Unique Technology for Saturating Blood With Oxygen and Removing Carbon Dioxide

#Customers #Investment

Inspira Technologies and Genius Group Interviews to Air on Bloomberg TV on the RedChip Money Report(R)

Inspira(TM) Technologies to Present at the Planet MicroCap Showcase 2023 on Wednesday, April 26, 2023 in Las Vegas

#Partners

Keynotes, Educational Panels and 77 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, NV

Inspira™ Technologies Reports Fourth Quarter 2022 and Full Year Financial Results

Inspira™ Technologies Announces First in Human of HYLA™ Blood Sensor in Clinical Study

#Customers

Inspira™ Technologies Receives Approval from Sheba Medical Center to Conduct Clinical Study of the HYLA™ Blood Sensor

#Customers

Inspira™ Technologies Granted Patent by U.S. Patent Office for the INSPIRA™ ART System's Convertible Dual Lumen Cannula Device and Method of Use

Diamond Equity Research Initiates Coverage on Inspira Technologies Ltd. (NASDAQ: IINN)

Inspira™ Technologies Signs Strategic OEM Agreement with Terumo Cardiovascular

Inspira(TM) Technologies Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

Inspira™ Technologies Interview to Air on Bloomberg U.S. on the RedChip Money Report®

#Partners

Inspira™ Technologies Begins Manufacturing of the ALICE™ CPB Device, ahead of planned 2023 FDA submission

Inspira™ Technologies Signs Agreement to Conduct Clinical Study of HYLA™ Blood Sensor

#Partners

Inspira™ Technologies Reports Third Quarter 2022 Financial Results

#Investment #Partners

Inspira™ Technologies Signs a Strategic Agreement in Europe to potentially provide $26.1 for Deployment of 1,364 HYLA™ Blood Sensors

#Partners

Inspira™ Technologies Granted Patent by the Israeli Patent Office for Key Safety Component for the INSPIRA™ ART System

Inspira™ Technologies Develops a Non-Invasive Blood Sensor Designed to Alert Real-Time Change in Patients - Potentially Targets $2.5 Billion ABG Market

#Customers

Inspira Technologies Has Listed an FDA Class I 510(k) Exempt component of the ART system

#Customers

Inspira™ Technologies Reveals Next Generation Liby™ System, an Extracorporeal Membrane Oxygenation System, Targeting a $531 Million Global ECMO Market

#Investment #Customers

Inspira Technologies Announces Deployment Agreement in the Israeli Market to Target $15M

#Partners

Inspira Technologies Signs a Strategic Agreement in the U.S. to Target $212 Million for Inspira Over a 7-Year Period, Subject to Regulatory Approvals

#Partners

Inspira Technologies' "Artificial Lung" to Acquire a Digital Edge: The Company Contracted GlobalLogic, a Hitachi Group Company, for advanced digital product engineering services

#Partners

Inspira Technologies Reached Important Milestone as It Completed a Pump Bench Study

#Investment #Expand

Inspira Technologies and Ben-Gurion University Have Developed a Platform Designed to Prevent Blood Clotting in Inspira's ART System

#Partners #Investment

Inspira Technologies OXY B.H.N. Ltd Announces Closing of Initial Public Offering

#Public Trading

Inspira Technologies OXY B.H.N. Ltd Announces Pricing of Initial Public Offering

#Public Trading

Q&A: An intelligent oxygenation system that could eliminate need for ventilators

#Customers

הקורונה מטיסה את שאיפות ההנפקה של אינספירה

#Investment #Public Trading #Partners

Inspira Technologies Files U.S. Patent Application for its Innovative Respiratory Support Technology;Engages Leading U.S. Investment Bank for NASDAQ Listing

#Customers #Expand

Similar Companies

Driven by Finder AI

Primary sector

Total funding

Undisclosed

Funding stage

undefined

Number of employees

Founded

2/2018

Team Members

undefined

Contact Team

Affiliated Organizations

(undefined)

Locations

Israel

Photos & videos

(0)

No Data, yet.

Sorry, no content found under this section.

QTREX Quantum Business

Business models

Product stage

Geographic markets

Products

Sector

Primary:

Target Customer

Core Technology

QTREX Quantum Financials

Total funding Undisclosed

Market cap Undisclosed

Last funding Undisclosed

Funding stage undefined

Total rounds undefined

Investors undefined

Cumulative Funding Raised Over Time ($)

Public Offerings & Exits

Initial Public Offering EXIT

$16M

Jul 2021

Stock Exchange

NASDAQ

Valuation Undisclosed

$16M

Private Equity Funding

PIPE

$1.8M

Dec 2025

$1.8M

PIPE

$3.2M

Dec 2024

$3.2M

PIPE

$1.65M

Apr 2024

$1.65M

A Round

Undisclosed

Mar 2021

Undisclosed

Non-Equity Funding

Grant

$1M

Jun 2026

1 Grantors

$1M

QTREX Quantum Lifecycle

Cumulative Funding Raised Over Time ($)

Timeline

Employees Over Time

News Over Time

1 Investors

$1M

PIPE

$1.8M

Dec 2025

$1.8M

PIPE

$3.2M

Dec 2024

$3.2M

PIPE

$1.65M

Apr 2024

$1.65M

Stock Exchange

NASDAQ

Valuation Undisclosed

$16M

A Round

Undisclosed

Mar 2021

Undisclosed

News Over Time

News Articles